The biotech will both contribute to and draw from its findings. It'll also earn revenue from its par

U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal.

Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a

Twist Bioscience joins Eli Lilly's TuneLab platform, supplying high-throughput antibody data to

U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent

[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a mid-cap growth and value biotech company

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap

BWS Financial analyst Hamed Khorsand initiates coverage on Twist Bioscience (NASDAQ:TWST) with a

If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of eviden

UBS analyst Doug Schenkel initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rat

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap

Brandywine Managers LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ: T

Deutsche Bank AG acquired a new stake in Twist Bioscience Corporation (NASDAQ: TWST) in the undefine

Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from curren

Twist Bioscience Corp (NASDAQ:TWST) shares surged Wednesday after Anthropic named the company an ind

TWST shares surge after Anthropic names the company an independent evaluator in a new AI-driven prot

Twist Bioscience (TWST) stock jumped 17% after Anthropic chose the firm to test AI-designed proteins

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting str

Anthropic is preparing what could be the largest IPO of 2026, and it's telling investors the pitch g

On August 07, 2026, Twist Bioscience Corp (TWST) shares rose by 6.0%, bringing the current price to

Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)'s share price shot up 10.3% during mid

Piper Sandler analyst David Westenberg maintains Twist Bioscience (NASDAQ:TWST) with a Overweight

Twist Bioscience's stock has surged in 2026 on the back of improved growth and growing optimism abou

Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech compan

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”),

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”),

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, T

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and rai

First Trust Advisors LP acquired a new position in Twist Bioscience Corporation (NASDAQ: TWST) in th

Twist Bioscience Corporation (TWST) Q3 2026 Earnings Call Transcript

Twist Bioscience (NASDAQ: TWST) stock is up on strong Q3 results and raised guidance. AI drug discov

Twist Bioscience (NASDAQ:TWST) raises FY2026 sales outlook from $442.000 million-$447.000 million to

Twist Bioscience (NASDAQ:TWST) sees Q4 sales of $123.000 million-$124.000 million vs $117.546 millio

Canaccord Genuity analyst Kyle Mikson maintains Twist Bioscience (NASDAQ:TWST) with a Buy and rai

Evercore ISI Group analyst Vijay Kumar downgrades Twist Bioscience (NASDAQ:TWST) from Outperform

Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and rais

https://www.sec.gov/Archives/edgar/data/1581280/000110465926075726/tm2617605-1_s3asr.htm

TD Cowen analyst Brendan Smith maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the

Canaccord Genuity analyst Kyle Mikson initiates coverage on Twist Bioscience (NASDAQ:TWST) with a

Piper Sandler analyst David Westenberg initiates coverage on Twist Bioscience (NASDAQ:TWST) with

-LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform,

Twist Bioscience Corp (TWST) reported Q2 loss but exceeded sales guidance. CEO expects profitability

Top Wall Street analysts changed outlook on top names. Check analyst ratings page for full changes.

Top analysts change outlooks on top names: UBS raises price target for TD Synnex, BMO Capital raises

Leerink Partners analyst Puneet Souda upgrades Twist Bioscience (NASDAQ:TWST) from Market Perform

Barclays analyst Luke Sergott maintains Twist Bioscience (NASDAQ:TWST) with a Overweight and rais

Guggenheim analyst Subbu Nambi maintains Twist Bioscience (NASDAQ:TWST) with a Buy and raises the

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:TWST) with a Outperform and rai

Twist Bioscience posts wider Q2 loss, beats revenue estimates, raises FY26 outlook, and expands gene